Moving ahead, Rob Rowe, Regional Research Director and Head of Global Strategy at a large US bank is ‘ tactically bullish ’ on the back of continuing tech recovery and the markets “pricing in a soft ...

Discover the latest research on Ozempic and other GLP-1 medications, including potential uses in treating Alzheimer's and opioid and alcohol use disorders.

Alzheimer’s causes a gradual decline in memory, thinking, behaviour, and social skills, and it is the most common cause of ...

Global stock markets diverged Friday in an end to a week's trading dominated by earnings updates and angst over rising bond ...

Semaglutide outperformed 7 diabetes medications in reducing risk of Alzheimer's disease, according to a study of over 1 ...

Research suggests Ozempic could reduce Alzheimer's risk in type 2 diabetes, with a 67% lower diagnosis rate compared to ...

Ozempic and other GLP-1 drugs show promise not only in managing obesity and diabetes but also in reducing Alzheimer's risk. A ...

The University of Cincinnati's Alberto Espay, MD, commented to NBC News on new research published Oct. 24 that found ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim ...

The findings spell an uncertain future for hospitals and clinics that derive a significant portion of their revenues from ...

Semaglutide, the active ingredient in Ozempic and Wegovy, may lower the risk of Alzheimer’s disease.A new study suggests type 2 diabetes patients taking semaglu ...

A new study reveals that the active ingredient in drugs like Ozempic and Wegovy could lower the risk of developing ...